Integrin α5β1 as a novel therapeutic target in renal cancer

Vanitha Ramakrishnan, Vinay Bhaskar, Melvin Fox, Keith Wilson, John C. Cheville, Barbara A. Finck

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-angiogenics have shown efficacy in the treatment of renal cancer. Most current therapies target the VEGF pathway. In this chapter, we discuss the role of integrins, specifically α5β1, in angiogenesis. The integrin α5β1 is up-regulated on proliferating endothelial cells. The monoclonal antibody volocixi-mab is a potent, high-affinity inhibitor of α5β1. Inhibition of α5β1 function by volociximab results in the apoptosis of proliferating, but not resting, endothelial cells in vitro. Inhibitory activity of volociximab appears to be independent of the growth factor milieu, suggesting a potential role for this agent under pathological conditions where multiple growth factors are present. Additionally, in pre-clinical models of angiogenesis such as the cynomolgus choroidal neovascularization model, volociximab is effective at inhibiting lesion development. An assessment of the expression of α5β1 by immunohistochemistry in annotated samples of renal cancer suggest a relationship between α5β1 expression and clinical grade of the tumour. The analysis shows that the expression of this integrin was very high in the tumour vasculature in all the clinical grades of renal cancer tested. However, we found an increase in target expression on the tumour cells that correlated with worsening clinical grade. These results suggest an additional mechanism by which volociximab may provide clinical benefit. Volociximab may not only exert an anti-angiogenic effect but may also have a direct inhibitory effect on the tumour cells. A phase 1 clinical trial with volociximab has been completed in patients having a variety of tumour types. The results show that the antibody is well tolerated at doses up to 15 mg/kg weekly. No drug-related adverse events were noted, and the best clinical response seen so far is stable disease. Volociximab is currently undergoing further clinical testing, and is being assessed in pilot open label trials, in indications including renal cancer.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma: Molecular Targets and Clinical Applications
PublisherHumana Press
Pages195-209
Number of pages15
ISBN (Print)9781588297372
DOIs
StatePublished - 2009

Fingerprint

Kidney Neoplasms
Integrins
Neoplasms
Therapeutics
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Choroidal Neovascularization
Clinical Trials, Phase I
volociximab
Drug-Related Side Effects and Adverse Reactions
Vascular Endothelial Growth Factor A
Immunohistochemistry
Monoclonal Antibodies
Apoptosis
Antibodies

Keywords

  • Anti-angiogenic therapy
  • Integrins in angiogenesis
  • Renal cancer α5β1
  • Volociximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ramakrishnan, V., Bhaskar, V., Fox, M., Wilson, K., Cheville, J. C., & Finck, B. A. (2009). Integrin α5β1 as a novel therapeutic target in renal cancer. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications (pp. 195-209). Humana Press. https://doi.org/10.1007/978-1-59745-332-5_11

Integrin α5β1 as a novel therapeutic target in renal cancer. / Ramakrishnan, Vanitha; Bhaskar, Vinay; Fox, Melvin; Wilson, Keith; Cheville, John C.; Finck, Barbara A.

Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. p. 195-209.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ramakrishnan, V, Bhaskar, V, Fox, M, Wilson, K, Cheville, JC & Finck, BA 2009, Integrin α5β1 as a novel therapeutic target in renal cancer. in Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, pp. 195-209. https://doi.org/10.1007/978-1-59745-332-5_11
Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin α5β1 as a novel therapeutic target in renal cancer. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press. 2009. p. 195-209 https://doi.org/10.1007/978-1-59745-332-5_11
Ramakrishnan, Vanitha ; Bhaskar, Vinay ; Fox, Melvin ; Wilson, Keith ; Cheville, John C. ; Finck, Barbara A. / Integrin α5β1 as a novel therapeutic target in renal cancer. Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. pp. 195-209
@inbook{190ca32fea9f4abd8f13576b6ed1fd1b,
title = "Integrin α5β1 as a novel therapeutic target in renal cancer",
abstract = "Anti-angiogenics have shown efficacy in the treatment of renal cancer. Most current therapies target the VEGF pathway. In this chapter, we discuss the role of integrins, specifically α5β1, in angiogenesis. The integrin α5β1 is up-regulated on proliferating endothelial cells. The monoclonal antibody volocixi-mab is a potent, high-affinity inhibitor of α5β1. Inhibition of α5β1 function by volociximab results in the apoptosis of proliferating, but not resting, endothelial cells in vitro. Inhibitory activity of volociximab appears to be independent of the growth factor milieu, suggesting a potential role for this agent under pathological conditions where multiple growth factors are present. Additionally, in pre-clinical models of angiogenesis such as the cynomolgus choroidal neovascularization model, volociximab is effective at inhibiting lesion development. An assessment of the expression of α5β1 by immunohistochemistry in annotated samples of renal cancer suggest a relationship between α5β1 expression and clinical grade of the tumour. The analysis shows that the expression of this integrin was very high in the tumour vasculature in all the clinical grades of renal cancer tested. However, we found an increase in target expression on the tumour cells that correlated with worsening clinical grade. These results suggest an additional mechanism by which volociximab may provide clinical benefit. Volociximab may not only exert an anti-angiogenic effect but may also have a direct inhibitory effect on the tumour cells. A phase 1 clinical trial with volociximab has been completed in patients having a variety of tumour types. The results show that the antibody is well tolerated at doses up to 15 mg/kg weekly. No drug-related adverse events were noted, and the best clinical response seen so far is stable disease. Volociximab is currently undergoing further clinical testing, and is being assessed in pilot open label trials, in indications including renal cancer.",
keywords = "Anti-angiogenic therapy, Integrins in angiogenesis, Renal cancer α5β1, Volociximab",
author = "Vanitha Ramakrishnan and Vinay Bhaskar and Melvin Fox and Keith Wilson and Cheville, {John C.} and Finck, {Barbara A.}",
year = "2009",
doi = "10.1007/978-1-59745-332-5_11",
language = "English (US)",
isbn = "9781588297372",
pages = "195--209",
booktitle = "Renal Cell Carcinoma: Molecular Targets and Clinical Applications",
publisher = "Humana Press",

}

TY - CHAP

T1 - Integrin α5β1 as a novel therapeutic target in renal cancer

AU - Ramakrishnan, Vanitha

AU - Bhaskar, Vinay

AU - Fox, Melvin

AU - Wilson, Keith

AU - Cheville, John C.

AU - Finck, Barbara A.

PY - 2009

Y1 - 2009

N2 - Anti-angiogenics have shown efficacy in the treatment of renal cancer. Most current therapies target the VEGF pathway. In this chapter, we discuss the role of integrins, specifically α5β1, in angiogenesis. The integrin α5β1 is up-regulated on proliferating endothelial cells. The monoclonal antibody volocixi-mab is a potent, high-affinity inhibitor of α5β1. Inhibition of α5β1 function by volociximab results in the apoptosis of proliferating, but not resting, endothelial cells in vitro. Inhibitory activity of volociximab appears to be independent of the growth factor milieu, suggesting a potential role for this agent under pathological conditions where multiple growth factors are present. Additionally, in pre-clinical models of angiogenesis such as the cynomolgus choroidal neovascularization model, volociximab is effective at inhibiting lesion development. An assessment of the expression of α5β1 by immunohistochemistry in annotated samples of renal cancer suggest a relationship between α5β1 expression and clinical grade of the tumour. The analysis shows that the expression of this integrin was very high in the tumour vasculature in all the clinical grades of renal cancer tested. However, we found an increase in target expression on the tumour cells that correlated with worsening clinical grade. These results suggest an additional mechanism by which volociximab may provide clinical benefit. Volociximab may not only exert an anti-angiogenic effect but may also have a direct inhibitory effect on the tumour cells. A phase 1 clinical trial with volociximab has been completed in patients having a variety of tumour types. The results show that the antibody is well tolerated at doses up to 15 mg/kg weekly. No drug-related adverse events were noted, and the best clinical response seen so far is stable disease. Volociximab is currently undergoing further clinical testing, and is being assessed in pilot open label trials, in indications including renal cancer.

AB - Anti-angiogenics have shown efficacy in the treatment of renal cancer. Most current therapies target the VEGF pathway. In this chapter, we discuss the role of integrins, specifically α5β1, in angiogenesis. The integrin α5β1 is up-regulated on proliferating endothelial cells. The monoclonal antibody volocixi-mab is a potent, high-affinity inhibitor of α5β1. Inhibition of α5β1 function by volociximab results in the apoptosis of proliferating, but not resting, endothelial cells in vitro. Inhibitory activity of volociximab appears to be independent of the growth factor milieu, suggesting a potential role for this agent under pathological conditions where multiple growth factors are present. Additionally, in pre-clinical models of angiogenesis such as the cynomolgus choroidal neovascularization model, volociximab is effective at inhibiting lesion development. An assessment of the expression of α5β1 by immunohistochemistry in annotated samples of renal cancer suggest a relationship between α5β1 expression and clinical grade of the tumour. The analysis shows that the expression of this integrin was very high in the tumour vasculature in all the clinical grades of renal cancer tested. However, we found an increase in target expression on the tumour cells that correlated with worsening clinical grade. These results suggest an additional mechanism by which volociximab may provide clinical benefit. Volociximab may not only exert an anti-angiogenic effect but may also have a direct inhibitory effect on the tumour cells. A phase 1 clinical trial with volociximab has been completed in patients having a variety of tumour types. The results show that the antibody is well tolerated at doses up to 15 mg/kg weekly. No drug-related adverse events were noted, and the best clinical response seen so far is stable disease. Volociximab is currently undergoing further clinical testing, and is being assessed in pilot open label trials, in indications including renal cancer.

KW - Anti-angiogenic therapy

KW - Integrins in angiogenesis

KW - Renal cancer α5β1

KW - Volociximab

UR - http://www.scopus.com/inward/record.url?scp=84892044584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892044584&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-332-5_11

DO - 10.1007/978-1-59745-332-5_11

M3 - Chapter

AN - SCOPUS:84892044584

SN - 9781588297372

SP - 195

EP - 209

BT - Renal Cell Carcinoma: Molecular Targets and Clinical Applications

PB - Humana Press

ER -